We found NDA135b to target tumor cells, but it binds to granulocytes
2019
Knockdown of microRNA-135b in Mammary Carcinoma by Targeted Nanodiamonds: Potentials and Pitfalls of In Vivo Applications
Key concepts
Scholarcy highlights
- Breast cancer is one of the most frequent women cancers worldwide and results in 13% of total cancer deaths
- In order to restore microRNA homeostasis resulting in impairment of tumor growth and its sensitization to conventional therapy, synthetic RNA is introduced into cancer cells using suitable carriers
- Such synthetic RNA can be designed to target microRNA overexpressed in tumor cells
- We focus on high-pressure and high-temperature ND with multiple coatings consisting of tumor antigen, polymer link, and sequence-specific antimiR
- Unbound PEI and Tf were removed by centrifugation and repeated dispersion of the NDs fraction in sterile deionized water in ND concentration 1 mg/mL.-PEI-coated ND were kept in a sonication bath, and immediately incubated for 1 h at room temperature with 270 μg of RNA
- Our presumption was based on the result mentioned in Figure 3d showing that in total, 4% of macrophages in our MF samples express transferrin receptor
- We found significantly increased amount of lactate dehydrogenase only in cells stimulated with A135b without difference in carrier
- Comparing the two different in vivo administrations, the localized intratumoral application was effective in order to knockdown target microRNA-135b and exhibited no leakage of NDA135b into bodily fluids or other tissues
Need more features? Save interactive summary cards to your Scholarcy Library.